ADIA (Adia Med) Ending Cash Position: $0.14 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADIA Adia Med Inc ADIA
14 GF Score
Price $0.15
! 4 Warning Signs
View Full Analysis

What is Adia Med Ending Cash Position?

Adia Med ADIA 14 Ending Cash Position is $0.14 Mil as of Mar. 2026. GuruFocus rates ADIA with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Adia Med's Ending Cash Position for the quarter that ended in Mar. 2026 was $0.14 Mil.

Adia Med's quarterly Ending Cash Position declined from Sep. 2025 ($0.15 Mil) to Dec. 2025 ($0.08 Mil) but then increased from Dec. 2025 ($0.08 Mil) to Mar. 2026 ($0.14 Mil).

Adia Med's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.01 Mil) and increased from Dec. 2024 ($0.01 Mil) to Dec. 2025 ($0.08 Mil).

Adia Med Ending Cash Position Related Terms

Adia Med Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Adia Med's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adia Med Ending Cash Position Chart

Adia Med Annual Data
Trend Dec24 Dec25
Ending Cash Position
0.01 0.08

Adia Med Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial 0.04 0.11 0.15 0.08 0.14
ADIA
14GF Score
Adia Med Inc ADIA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adia Med Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Adia Med's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.006+0.073
=0.08

Adia Med's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.079+0.058
=0.14

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.14 Mil mean?
Adia Med (ADIA) has a Ending Cash Position of $0.14 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adia Med and its competitors.
Is Adia Med's Ending Cash Position too high?
Adia Med's current Ending Cash Position is $0.14 Mil. Overall, Adia Med has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Adia Med's Ending Cash Position compare to GBCS and CCM?
Adia Med's Ending Cash Position of $0.14 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Adia Med and its competitors. Adia Med's current Ending Cash Position is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adia Med stock overvalued right now?
Adia Med (ADIA) has a current Ending Cash Position of $0.14 Mil. The current Ending Cash Position is $0.14 Mil. Adia Med's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Adia Med (ADIA), the current Ending Cash Position is $0.14 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adia Med Business Description

Address 1561 West Fairbanks Avenue, Suite 205, Winter Park, FL, USA, 32789
Adia Nutrition Inc focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Its products and the deployment of the therapies utilizing its products address various orthopedic issues, pain management, and wound repair. In addition, its products are able to be utilized in various other therapies to address anti-aging issues and other tissue repair desires. It operates in three segments The Biolete segment comprises the sale of supplements; Adia Med performs stem cell treatments to patients; and Adia Labs procures and sells stem cell products to outside clinics or to Adia Med. It derives revenue from Sales of supplements, Medical procedures, Sales of biologics and ancillary products.
14GF Score

Get the complete analysis for ADIA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price